On the Relevance of Soft Tissue Sarcomas Metabolic Landscape Mapping

Area of Science:

• Oncology
• Biochemistry
• Genomics

Background:

• Soft tissue sarcomas (STS) have a poor prognosis, with current treatments lacking personalization and failing to account for specific subtype and metabolic differences.
• The limited availability of precision therapies for STS is attributed to a scarcity of research into sarcomagenesis mechanisms.
• There is a critical need to enhance STS diagnostic accuracy, refine classification, and identify prognostic biomarkers.

Purpose of the Study:

• To review the application of omics technologies in soft tissue sarcomas.
• To analyze the metabolic landscape of STS through a detailed examination of existing studies.
• To underscore the potential of metabolomics in understanding and treating STS.

Main Methods:

• Comprehensive literature review of single-omics and multi-omics studies in STS.
• Analysis of metabolomics approaches including mass spectrometry (MS), MS imaging, and nuclear magnetic resonance (NMR) spectroscopy.
• Evaluation of emerging methods like advanced chromatography and flow cytometry for metabolic pathway analysis.

Main Results:

• Metabolomics offers unique insights into the metabolic adaptations supporting sarcomagenesis, whether as a standalone or integrated multi-omics approach.
• Current metabolomic characterization of STS is limited, but existing studies using MS and NMR have yielded valuable data.
• New analytical techniques promise to enable therapeutic targeting of metabolic pathways and monitoring of treatment response.

Conclusions:

• Omics studies, particularly metabolomics, are crucial for deciphering sarcomagenesis and improving STS diagnosis and classification.
• Further research into the STS metabolome is warranted to identify novel biomarkers and therapeutic targets.
• Advancements in metabolomic technologies will facilitate the development of personalized treatment strategies for STS.